Every 10-Q that PHARM-BIO SERV INC (PBSV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PBSV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBSV filings page.
Pharma-Bio Serv, Inc. (PBSV) reported higher revenue and a return to profitability for the nine months ended July 31, 2026. Revenue was $7.3 million, up about $0.5 million from a year earlier, driven mainly by growth in Puerto Rico and Europe, partially offset by lower U.S. consulting revenue. Gross margin stayed stable at about 31.6%. Selling, general and administrative expenses fell to $2.3 million, reflecting lower occupancy and other planned savings, helping swing results to net income of $0.25 million versus a prior-year loss.
The balance sheet remains lightly leveraged, with total liabilities of $1.0 million and stockholders’ equity of $10.4 million, including $1.5 million in cash and $7.1 million in U.S. Treasury marketable securities and working capital of about $10.2 million. The company paid a $0.075 per share cash dividend totaling $1.72 million and continued modest share repurchases. Revenue is concentrated, with four global groups accounting for more than half of sales, and the company awaits extension of a key Puerto Rico tax grant while benefiting from another tax incentive through 2039.
Pharma-Bio Serv, Inc. reported modest growth and stronger profitability for the quarter and six months ended April 30, 2026. Revenue reached $2.7 million for the quarter and $5.0 million for six months, up slightly from the prior year as Puerto Rico and Europe offset softer U.S. consulting activity.
Net income rose to $233,000 for the quarter and $266,000 for six months, an increase of approximately $0.1 million and $0.2 million versus last year, helped by lower selling, general and administrative expenses and steady gross margins around the low‑30% range. Basic and diluted earnings per share were $0.010 for the quarter and $0.012 year‑to‑date.
The balance sheet remained conservative, with total assets of $11.5 million, including $1.8 million in cash and $6.7 million in marketable U.S. Treasury securities. Working capital was about $10.2 million, even after paying a $0.075 per share cash dividend totaling $1.72 million and repurchasing a small number of shares. Management believes existing liquidity and cash generation are sufficient to fund operations and its stock repurchase program.
Pharma-Bio Serv, Inc. reported nearly flat operations but remained profitable for the quarter ended January 31, 2026. Revenue was about $2.3 million, down from $2.5 million a year earlier, as U.S. and Europe consulting projects declined while Puerto Rico inched up.
Gross margin was stable at 31.5%, with a small operating loss of $94,535 offset by $131,025 of other income, mainly interest and foreign exchange gains, yielding net income of $32,860. Earnings per share were effectively breakeven at $0.001.
The company ended the quarter with $5.8 million in cash and $4.8 million in marketable U.S. Treasury securities, and working capital of about $10 million. It declared a $0.075 per-share cash dividend (about $1.72 million) and repurchased 3,100 shares at $0.54. Headquarters moved to a virtual model after its only long-term lease expired, and management believes existing resources are sufficient to fund operations beyond the next twelve months.
Pharma-Bio Serv, Inc. (PBSV) discloses share counts, tax items, repurchases and customer concentration. The company reports 10,000,000 authorized shares with 23,519,672 issued and 22,920,442 outstanding at July 31, 2025, and notes 599,230 common shares held in treasury at that date. Under U.S. tax reforms, a 100% exemption on certain foreign-source dividends is noted while GILTI subjects foreign subsidiary earnings to a reduced U.S. tax rate of 10.5%. The Transition Tax payment period runs eight years through the companys second quarter of fiscal 2026. The Spanish subsidiary tax rate is 25%. During the period, the company repurchased 536,258 and 498,557 common shares for aggregate amounts of $507,112 and $484,871, respectively, and paid $1,719,918 on March 20, 2025. Revenue concentration from certain global affiliated groups rose to 53.8% for the nine months ended July 31, 2025, and amounts due from those affiliates represented 55.3% of total accounts receivable at July 31, 2025.